Confo Therapeutics, a biotechnology company and spin-off from VUB and VIB, has shared encouraging new results for a drug candidate designed to treat a serious complication of weight-loss surgery. The drug candidate, called CFTX-2034, aims to treat a condition known as post-bariatric hypoglycemia (PBH).